Valneva SE Logo

Valneva SE

ISIN: FR0004056851 | Ticker: VLA | LEI: 969500DIVIP5VKNW4948
Sector: Health CareSub-Industry: Pharmaceuticals
Country: France

About Valneva SE

Company Description

Valneva is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need. The Company has several vaccines in development, including unique vaccines against Lyme disease, COVID-19 and chikungunya. Valneva’s portfolio also includes two commercial vaccines for travelers.

Year founded

2013

Served area

Worldwide

Headcount

762

Headquarters

6 Rue Alain Bombard, 44800 Saint-Herblain – France

Financial statements

Download as Excel
Line item in (eur) 01.01.2020 01.01.2021 01.01.2022 01.01.2023
Assets N/A 449,164,000.00 817,352,000.00 621,344,000.00
Noncurrent Assets N/A 140,737,000.00 231,520,000.00 196,685,000.00
Property Plant And Equipment N/A 34,779,000.00 125,545,000.00 112,435,000.00
Intangible Assets Other Than Goodwill N/A 35,409,000.00 32,700,000.00 28,711,000.00
Investment Accounted For Using Equity Method N/A 2,130,000.00 2,124,000.00 0.00
Deferred Tax Assets N/A 5,570,000.00 3,582,000.00 5,637,000.00
Other Noncurrent Assets N/A 19,476,000.00 19,282,000.00 8,299,000.00
Current Assets N/A 308,427,000.00 585,832,000.00 424,660,000.00
Inventories N/A 26,933,000.00 124,098,000.00 35,104,000.00
Current Trade Receivables N/A 19,232,000.00 44,013,000.00 23,912,000.00
Cash and cash equivalents 64,439,000.00 204,394,000.00 346,642,000.00 N/A
Noncurrent Assets Or Disposal Groups Classified As Held For Sale Or As Held For Distribution To Owners N/A N/A 0.00 2,134,000.00
Current Restricted Cash And Cash Equivalents 0.00 41,000.00 44,000.00 2,898,000.00
Other Current Assets N/A 57,828,000.00 71,036,000.00 74,079,000.00
Equity And Liabilities N/A 449,164,000.00 817,352,000.00 621,344,000.00
Equity 135,153,000.00 77,422,000.00 170,581,000.00 219,797,000.00
Issued Capital N/A 13,646,000.00 15,786,000.00 20,755,000.00
Retained Earnings Profit Loss For Reporting Period N/A N/A -73,425,000.00 -143,279,000.00
Retained Earnings Excluding Profit Loss For Reporting Period N/A N/A -233,549,000.00 -306,974,000.00
Share Premium N/A 244,984,000.00 409,258,000.00 594,043,000.00
Other Reserves N/A 52,342,000.00 52,512,000.00 55,252,000.00
Equity Attributable To Owners Of Parent N/A 77,422,000.00 170,581,000.00 219,797,000.00
Liabilities N/A 371,742,000.00 646,771,000.00 401,547,000.00
Noncurrent Liabilities N/A 195,872,000.00 277,791,000.00 124,156,000.00
Noncurrent Provisions N/A 2,358,000.00 8,308,000.00 1,320,000.00
Noncurrent Contract Liabilities N/A 58,000.00 4,741,000.00 0.00
Deferred Tax Liabilities N/A 412,000.00 1,290,000.00 694,000.00
Other Noncurrent Liabilities N/A 72,000.00 69,000.00 116,000.00
Longterm Borrowings N/A 46,375,000.00 50,726,000.00 87,227,000.00
Current Liabilities N/A 175,870,000.00 368,979,000.00 277,392,000.00
Current Provisions N/A 10,169,000.00 48,708,000.00 31,257,000.00
Current Contract Liabilities N/A 89,578,000.00 124,017,000.00 9,411,000.00
Current Tax Liabilities Current N/A 0.00 83,000.00 532,000.00
Other Current Liabilities N/A 2,841,000.00 4,950,000.00 5,523,000.00
Line item in (eur) 01.01.2019/
01.01.2020
01.01.2020/
01.01.2021
01.01.2021/
01.01.2022
01.01.2022/
01.01.2023
Revenue 126,196,000.00 110,321,000.00 348,086,000.00 361,303,000.00
Revenue From Sale Of Goods 129,511,000.00 65,938,000.00 62,984,000.00 114,797,000.00
Other Revenue -3,315,000.00 44,383,000.00 285,101,000.00 246,506,000.00
Profit Loss From Operating Activities -811,000.00 -55,120,000.00 -61,390,000.00 -113,443,000.00
Finance Income 1,449,000.00 516,000.00 249,000.00 260,000.00
Finance Costs 3,082,000.00 10,738,000.00 16,964,000.00 19,054,000.00
Share Of Profit Loss Of Associates And Joint Ventures Accounted For Using Equity Method 1,574,000.00 -133,000.00 -5,000.00 9,000.00
Profit Loss Before Tax -870,000.00 -65,302,000.00 -69,979,000.00 -144,815,000.00
Income Tax Expense Continuing Operations 874,000.00 -909,000.00 3,446,000.00 -1,536,000.00
Profit (loss) -1,744,000.00 -64,393,000.00 -73,425,000.00 -143,279,000.00
Line item in (eur) 01.01.2020 01.01.2021 01.01.2022 01.01.2023
Profit (loss) -1,744,000.00 -64,393,000.00 -73,425,000.00 -143,279,000.00
Other Adjustments For Noncash Items 12,704,000.00 37,941,000.00 56,476,000.00 44,070,000.00
Cash Flows From Used In Operations 7,875,000.00 139,759,000.00 78,532,000.00 -245,189,000.00
Income Taxes Paid Refund Classified As Operating Activities 2,346,000.00 2,021,000.00 1,631,000.00 154,000.00
Cash Flows From Used In Operating Activities 5,529,000.00 137,738,000.00 76,901,000.00 -245,343,000.00
Proceeds From Sales Of Property Plant And Equipment Classified As Investing Activities N/A 0.00 0.00 8,000.00
Purchase Of Property Plant And Equipment Classified As Investing Activities 10,502,000.00 18,936,000.00 92,229,000.00 29,246,000.00
Proceeds From Sales Of Intangible Assets Classified As Investing Activities 0.00 24,000.00 0.00 0.00
Purchase Of Intangible Assets Classified As Investing Activities 382,000.00 535,000.00 942,000.00 76,000.00
Interest Received Classified As Investing Activities 199,000.00 107,000.00 54,000.00 260,000.00
Cash Flows From Used In Investing Activities -10,685,000.00 -19,340,000.00 -93,116,000.00 -29,054,000.00
Proceeds From Borrowings Classified As Financing Activities 11,781,000.00 50,266,000.00 859,000.00 39,331,000.00
Repayments Of Borrowings Classified As Financing Activities 11,684,000.00 21,995,000.00 1,956,000.00 1,793,000.00
Payments Of Lease Liabilities Classified As Financing Activities 2,709,000.00 2,111,000.00 2,805,000.00 3,048,000.00
Interest Paid Classified As Financing Activities 2,621,000.00 4,711,000.00 8,417,000.00 9,211,000.00
Cash Flows From Used In Financing Activities -7,696,000.00 21,740,000.00 154,504,000.00 215,116,000.00
Increase (decrease) in cash and cash equivalents before effect of exchange rate changes -12,852,000.00 140,138,000.00 138,288,000.00 -59,282,000.00
Effect Of Exchange Rate Changes On Cash And Cash Equivalents 207,000.00 -183,000.00 3,960,000.00 -828,000.00
Cash and cash equivalents 64,439,000.00 204,394,000.00 346,642,000.00 N/A

Please note that some sums might not add up.

Filings & Publications

Insider Trades

Date Trading entity / Person Association Trade type Volume
18.03.24 None Other Buy EUR 0.00
03.01.24 None Other Other EUR 0.00
20.06.23 None Other Sell EUR 1,406,228.50
19.06.23 None Other Sell EUR 209,629.26
16.06.23 None Other Sell EUR 582,493.06
15.06.23 None Other Sell EUR 189,503.78
14.06.23 None Other Sell EUR 1,519,914.11
13.06.23 None Other Sell EUR 187,922.37
12.06.23 None Other Sell EUR 733,782.57
10.05.23 None Other Buy EUR 0.00

Capital markets information

ISIN

FR0004056851

LEI

969500DIVIP5VKNW4948

Sector

Health Care

Industry Group

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Pharmaceuticals

Sub-Industry

Pharmaceuticals

Listed Stock Exchange

Euronext Paris

Main Stock Exchange

Contact Investor Relations department

Stay up to date

Keep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.